|
1
|
Sechler M, Cizmic AD, Avasarala S, Van
Scoyk M, Brzezinski C, Kelley N, Bikkavilli RK and Winn RA:
Non-small-cell lung cancer: Molecular targeted therapy and
personalized medicine - drug resistance, mechanisms, and
strategies. Pharmgenomics Pers Med. 6:25–36. 2013.PubMed/NCBI
|
|
2
|
Doebele RC, Pilling AB, Aisner DL,
Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ,
Heasley LE, Franklin WA, et al: Mechanisms of resistance to
crizotinib in patients with ALK gene rearranged non-small cell lung
cancer. Clin Cancer Res. 18:1472–1482. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chang A: Chemotherapy, chemoresistance and
the changing treatment landscape for NSCLC. Lung Cancer. 71:3–10.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Willers H, Azzoli CG, Santivasi WL and Xia
F: Basic mechanisms of therapeutic resistance to radiation and
chemotherapy in lung cancer. Cancer J. 19:200–207. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shimura T, Noma N, Sano Y, Ochiai Y,
Oikawa T, Fukumoto M and Kunugita N: AKT-mediated enhanced aerobic
glycolysis causes acquired radioresistance by human tumor cells.
Radiother Oncol. 112:302–307. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhao Y, Butler EB and Tan M: Targeting
cellular metabolism to improve cancer therapeutics. Cell Death Dis.
4:e5322013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ameres SL and Zamore PD: Diversifying
microRNA sequence and function. Nat Rev Mol Cell Biol. 14:475–488.
2013. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zheng T, Wang J, Chen X and Liu L: Role of
microRNA in anticancer drug resistance. Int J Cancer. 126:2–10.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ma J, Dong C and Ji C: MicroRNA and drug
resistance. Cancer Gene Ther. 17:523–531. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gwak HS, Kim TH, Jo GH, Kim YJ, Kwak HJ,
Kim JH, Yin J, Yoo H, Lee SH and Park JB: Silencing of microRNA-21
confers radio-sensitivity through inhibition of the PI3K/AKT
pathway and enhancing autophagy in malignant glioma cell lines.
PLoS One. 7:e474492012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin CW, Li XR, Zhang Y, Hu G, Guo YH, Zhou
JY, Du J, Lv L, Gao K, Zhang Y and Deng H: TAp63 suppress
metastasis via miR-133b in colon cancer cells. Br J Cancer.
110:2310–2320. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao Y, Huang J, Zhang L, Qu Y, Li J, Yu
B, Yan M, Yu Y, Liu B and Zhu Z: MiR-133b is frequently decreased
in gastric cancer and its overexpression reduces the metastatic
potential of gastric cancer cells. BMC Cancer. 14:342014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen XN, Wang KF, Xu ZQ, Li SJ, Liu Q, Fu
DH, Wang X and Wu B: MiR-133b regulates bladder cancer cell
proliferation and apoptosis by targeting Bcl-w and Akt1. Cancer
Cell Int. 14:702014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Crawford M, Batte K, Yu L, Wu X, Nuovo GJ,
Marsh CB, Otterson GA and Nana-Sinkam SP: MicroRNA 133B targets
pro-survival molecules MCL-1 and BCL2L2 in lung cancer. Biochem
Biophys Res Commun. 388:483–489. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kano M, Seki N, Kikkawa N, Fujimura L,
Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M and
Matsubara H: miR-145, miR-133a and miR-133b: Tumor-suppressive
miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J
Cancer. 127:2804–2814. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dai A, Sun H, Fang T, Zhang Q, Wu S, Jiang
Y, Ding L, Yan G and Hu Y: MicroRNA-133b stimulates ovarian
estradiol synthesis by targeting Foxl2. FEBS Lett. 587:2474–2482.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shen L, Li J, Xu L, Ma J, Li H, Xiao X,
Zhao J and Fang L: miR-497 induces apoptosis of breast cancer cells
by targeting Bcl-w. Exp Ther Med. 3:475–480. 2012.PubMed/NCBI
|
|
20
|
Wong N, Ojo D, Yan J and Tang D: PKM2
contributes to cancer metabolism. Cancer Lett. 356:184–191. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Israelsen WJ, Dayton TL, Davidson SM,
Fiske BP, Hosios AM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW,
et al: PKM2 isoform-specific deletion reveals a differential
requirement for pyruvate kinase in tumor cells. Cell. 155:397–409.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Koukourakis MI, Giatromanolaki A,
Panteliadou M, Pouliliou SE, Chondrou PS, Mavropoulou S and
Sivridis E: Lactate dehydrogenase 5 isoenzyme overexpression
defines resistance of prostate cancer to radiotherapy. Br J Cancer.
110:2217–2223. 2014. View Article : Google Scholar : PubMed/NCBI
|
